Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.
Huang D, Lin G, Chu Q, Hu Y, Wang J, Wang Z, Yang F, Zhong W, Zhou C, Zhu B, Ai X, Cao B, Cao Y, Chen M, Chen X, Chu T, Duan J, Fan Y, Fang Y, Feng S, Feng W, Guo H, Han C, He Y, Hong S, Hu J, Huang M, Huang Y, Jiang D, Jiang K, Jiang R, Jin B, Jin S, Li J, Li M, Li Z, Li C, Lin J, Liu A, Liu SM, Liu Y, Liu Z, Liu Z, Liu Z, Liu Z, Liu Z, Lu Y, Lv T, Ma Z, Miao Q, Peng M, Pu X, Ren XB, Shan J, Shan J, Shen P, Shen B, Shi M, Song Y, Song Z, Su C, Sun J, Tian P, Wang J, Wang F, Wang H, Wang J, Wang Q, Wang W, Wang Y, Wu L, Wu F, Xia Y, Xie C, Xie C, Xin T, Xiong J, Xu H, Xu S, Xu Y, Xu B, Xu C, Yan X, Yang Z, Yao W, Yu Y, Feng Y, Yu Z, Yu Y, Yue D, Zhang H, Zhang H, Zhang L, Zhang L, Zhang Q, Zhang T, Zhang B, Zhao J, Zhao M, Zheng X, Zhong F, Zhou J, Zhou P, Zhu Z, Zou J, Zou Z. Huang D, et al. Among authors: zhang l, zhang b, zhang q, zhang t, zhang h. Thorac Cancer. 2023 Dec;14(34):3421-3429. doi: 10.1111/1759-7714.15157. Epub 2023 Nov 14. Thorac Cancer. 2023. PMID: 37963454 Free PMC article.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: zhang t, zhang h, zhang y. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
Zhang H, Wan Y, Wang H, Cai J, Yu J, Hu S, Fang Y, Gao J, Jiang H, Yang M, Liang C, Jin R, Tian X, Ju X, Hu Q, Jiang H, Li Z, Wang N, Sun L, Leung AWK, Wu X, Qian X, Qian M, Li CK, Yang J, Tang J, Zhu X, Shen S, Zhang L, Pui CH, Zhai X. Zhang H, et al. Among authors: zhang l. Cancer. 2023 Jun 1;129(11):1691-1703. doi: 10.1002/cncr.34741. Epub 2023 Mar 21. Cancer. 2023. PMID: 36943767
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.
Wang Y, Fu S, Zhang X, Du W, Luo L, Jiang Y, Zhou Y, Zhao Y, Yang Y, Zhao H, Fang W, Huang Y, Zhang L, Hong S. Wang Y, et al. Among authors: zhang l, zhang x. Front Immunol. 2023 May 29;14:1151385. doi: 10.3389/fimmu.2023.1151385. eCollection 2023. Front Immunol. 2023. PMID: 37313402 Free PMC article.
Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
Zhao S, Chen K, Shi X, Sun J, Fang W, Huang Y, Zhang L. Zhao S, et al. Among authors: zhang l. Clin Lung Cancer. 2023 Nov;24(7):e254-e258. doi: 10.1016/j.cllc.2023.06.009. Epub 2023 Jun 15. Clin Lung Cancer. 2023. PMID: 37442748 Clinical Trial.
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Wang J, Zhang B, Peng L, Liu X, Sun J, Su C, Wang H, Zhao Z, Si L, Duan J, Zhang H, Li M, Zhu B, Zhang L, Li J, Guo J, Luo R, Qiu W, Ye D, Chu Q, Cui J, Dong X, Fan Y, Gao Q, Guo Y, He Z, Li W, Lin G, Liu L, Liu Y, Qin H, Ren S, Ren X, Wang Y, Xue J, Yang Y, Yang Z, Yue L, Zhan X, Zhang J, Ma J, Qin S, Wang B. Wang J, et al. Among authors: zhang l, zhang b, zhang j, zhang h. Ther Adv Med Oncol. 2023 Jul 16;15:17588359231187205. doi: 10.1177/17588359231187205. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37484525 Free PMC article. Review.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. Zhao Y, et al. Among authors: zhang l, zhang w, zhang y. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37593227 Free PMC article.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, Zhuang W, Song W, Wang ZM, Li B, Xia Y, Zhao H, Zhang L. Zhao Y, et al. Among authors: zhang l. Lung Cancer. 2023 Oct;184:107355. doi: 10.1016/j.lungcan.2023.107355. Epub 2023 Aug 29. Lung Cancer. 2023. PMID: 37677918 Free article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Duan J, Wu L, Yang K, Zhao J, Zhao Y, Dai X, Li M, Xie Y, Yao Y, Zhao M, Zhou C, Ren X, Liu Z, Pan Y, Li Y, Liu B, Cheng Y, Miao L, Yu Q, Zhang Z, Liu X, Cui J, Zhang Y, Zhang L, Li X, Li X, Shen B, Chen B, Zeng S, Li B, Hu Y, Li L, Wu R, Song Q, Wang J. Duan J, et al. Among authors: zhang l, zhang z, zhang y. J Thorac Oncol. 2024 Feb;19(2):314-324. doi: 10.1016/j.jtho.2023.09.1449. Epub 2023 Sep 28. J Thorac Oncol. 2024. PMID: 37776953 Free article. Clinical Trial.
124,423 results
You have reached the last available page of results. Please see the User Guide for more information.